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Studies of complement components and activation products in cerebrospinal fluid (CSF) have suggested that complement is involved in several inflammatory diseases of the central nervous system (1 ) 4 The role of complement in the neurological syndrome associated with systemic lupus erythematosus is well documented (2) . Complement activation products can be detected in the CSF of patients with subacute sclerosing panencephalomyelitis and patients with Sj#{246}gren syndrome with central nervous system involvement (3) . Decreased CSF concentrations of complement C3 also occurduring exacerbations of multiple sclerosis(4).
As a result of the C3 activation, well-defined split products such as C3c are released from the complement cascade and reflect its activation by either the classical or the alternative pathway (5). Complement C3, the central molecule in the complement system, can be quantified by means of immunochemical methods [immunonephelometry (6), single radial immunodiffusion (7), electroimmunodiffusion (EU)) (8, 9), and radioimmunoassay (4)], but only the latest assays can be applied to biological fluids (especially CSF) in which the C3 concentration is low. Radioimmunoas8ay cannot be used routinely in all laboratories, and EU) has been proposed both with and without prior concentration of CSF. We report a new sensitive method for determining 
Apparatus.
We used a time-resolved fluorometer (1230 Arcus fluorometer), a 12-well aspirating-washing device (1296-024 Platewash), and an automated shaking device (1296-001 Plateshake), all from Kabi-Pharmacia (TJppsala,Sweden).
Reagents. We used a rabbit IgG antibody to human C3c (Dako, Copenhagen, Denmark) in phosphate buffer (0.1 molJL, pH 7.4). DELFIA europium-labeling kits were purchased from Kabi-Pharmacia. Each kit contains 0.2 mg of labeling reagent [N1-(p-isothiocyanatobenzyl)-diethylenetniamine-N', N2, N3, N3-tetraacetateeuropium], a 100 nmol/L europium standard, highly purified bovine serum albumin (BSA; 75 g/L in Ths-HC1, 50 mmol/L, pH 7.8, containing NaN3, 0.5 g/L), stabilizer, and enhancement solution (per liter, 15 mmol of 2-naphthoyltrifluoroacetone, 50 mmol of tni-n-octylphosphine oxide, 100 mmol of acetic acid, 6.8 minol of potassium hydrogen phthalate, and 1.0 g of Triton X-100 detergent). PD-b columns, Sepharose CL-6B, and Sephadex G-50 were from Pharmacia-Biotech (Uppsala, Sweden).
Buffers. The labeling buffer was 50 mmol/L NaHCO3, pH 8.5, containing 9 g of NaCl per liter. The elution buffer was 50 mmol/L Tris-HC1, pH 7.8, containing 9 g of NaCl and 0.5 g of NaN3 per liter. The coating buffer was K2HPO4 (50 mmol/L, pH 8.5), and the saturation solution was 50 mmoliL NaH2PO4 . 2H20 containing 60 g of sorbitol and 0.5 g of BSA per liter. The dilution buffer was 50 mmol/L Ths-HC1, pH 7.75, containing 9 g of NaCl, 5.0 g of BSA, 0.5 g of bovine y-globulin, 0.1 mL of Tween 40, and 20 mol of diethylene tniaminopentaacetic acid per liter. The washing solution was 100 mmol/L Tris-HC1, pH 7.75, plus 3 mL of Tween 20 per liter.
Standard.
Human serum standard OKU (Behring, Marburg, Germany), which has a C3 concentration of 0.69 g/L, was diluted with buffer to give six standard concentrations.
Labeling. Antibody to human C3c (150 ILL) was loaded onto a Sephadex G-50 column, which was rinsed with labeling buffer. Fractions of 500 &L were collected and protein absorbance was measured at 280 nm with an Ultraspec II (Kabi-Pharmacia). The fraction corresponding to peak absorbance (-2.5 mL of elution buffer) contained -'-1.0 g/L of IgG (an absorbance value of 1.34 corresponds to 1 g/L of IgG). A volume of 250 L (0.25 mg of IgG) was added to 0.05 mg of labeling reagent (containing the europium chelate) and incubated overnight at room temperature with gentle stirring.
Purification of europium-labeled
IgO. The preparation was purified by gel filtration through a PD-b column and eluted with buffer. Ten 1-mL fractions were collected and absorbance was read at 280 nm. Fractions corresponding to peak IgG absorbance were pooled.
Characterization of europium-labeled
IgG.
The amount of europium-labeled
antibody bound to anti-C3c was determined by measuring europium fluorescence relative to that of europium chloride standard (100 nmoIJL).
After addition of enhancement solution, the fluorescence of the europium-2-naphthoyl tnifluoroacetone chelate was measured as counts per second in a time-resolved fluorometer (1 s per well) .
The protein content of the europium-labeled antibody was quantified after absorbance was measured at 280 nm:
Protein (mol/L) = [A2 -(0.008 x Eu)J/(a X Mr) where 0.008 is the absorbance of bound aromatic thiourea, Eu is the amount of europium (in mol/L), a is absorbance of IgG (1.34), and Mr is the relative molecular mass of IgG (160 000). The europium/protein ratio was used to calculate the conjugation yield (7.5 europium molecules per IgG molecule). The labeled antibody was stored with stabilizer to improve the stability of the europium-labeled IgG. There was no loss of immunoreactivity during 6 months of storage at 4#{176}C. Linearity. The linearity of the method was determined by using the human serum standard diluted to C3 concentrations between 73 x i0 and 73 mgIL. Each dilution was assayed six times in three separate runs.
Detection limit. The detection limit of the assay was defined as the concentration corresponding to the mean plus 3 SDs of the zero standard fluorescence signal (for 15 replicates in five analytical runs).
Precision. The intra-assay precision of the TR-IFMA method was studied by analyzing the human serum 
Results

Linearity.
The calibration curve for the method was linear between 0.7 and 3650 pg/L. In standard use, the calibration curve for human serum standard can be established for C3 concentrations from 3.7 to 183 g/L (Figure 1) . Detection limit. The detection limit of the TR-IFMA for C3c was 0.1 jg/L.
Precision. The intra-assay coefficients of variation (CVs) were 4.8% for the 3.7 and 730 g/L C3 concentrations and 3.1% for 73 pg/L ( Table 1 patients infected with HIV, and 2.8 ± 2.2 and 4.1 ± 2.1 mg/L for the subjects with other neurological disorders by TR-IFMA and EU), respectively.
Discussion
The europium chelate provides a specificfluorescence signal that can be measured by means of the dissociation-enhancement technique. The europium label has the advantage of being nonradioactive and having a long shelf-life (10-14) . The degree of labeling was good (-7.5 molecules of europium per molecule of immunoglobulin) and there was no loss of immunoreactivity during 6 months of storage at 4#{176}C. The DELFIA methodology, a sandwich TR-IFMA, is well suited to measuring C3 in CSF. In addition, the low concentrations of europium and anti-C3c antibody (labeled or not) required for the assay make it relatively inexpensive. The procedure is convenient because the microwells also act as measurement cuvettes and the short measurement time per well makes it suitable for large series of samples (15) (16) (17) .
The values of the linear range (0.7-3650 g/L) and the detection limit (0.1 g/L) are very satisfactory. This , high sensitivity allows the C3 component to be measured in CSF, which contains very low concentrations of C3. Furthermore, the dose-response curves for serum and CSF complement C3 concentrations were not different. C3 can be assayed in CSF diluted only twofold, without falling outside the calibration range. A very small volume of sample (5 L of CSF) is required for the dilution. The intra-and inter-assay precision are good (CV <10.9%).
Although a good correlation was obtained with the EU) method, the C3 concentration values were slightly different (2.5 ± 1.5 mg/L in TR-IFMA vs 3.7 ± 1.8 mg/L in EU)) for the population studied. This may have been due to the sourceof the antisera (Dako for TR-IFMA and Hyland for EU)) and to the lower sensitivity of the EU) method (1 mg/L) (2) and could result in poorer precision for CSF samples containing very low concentrations of C3. The sensitivity and analytical range of the assay are compatible with the normal range and the usually encountered pathological values of C3 in CSF (e.g., in patients infected with H1V and patients with multiple sclerosis or other neurological disorders) (7). The normal interval for CSF C3 measured by TR-IFMA (2.4 mgfL) was comparable with the results of radioimmunoassay (3.03 mg/L) (4) and single radial immunodiffusion (2 mg/L) (8). In contrast, Annunziata and Volpi (9) reported lower concentrations (1.3 ± 0.01 mg/L) but assayed C3 after prior concentration of CSF; some C3 may have been lost during this step.
The excellent criteria of reliability of this technique, particularly its good sensitivity, makes it a suitable alternative for assaying C3 in CSF and other biological fluids containing very low concentrations of C3 (synovial fluid, joint fluid, etc.).
